Bausch Health Companies Inc. vs BioCryst Pharmaceuticals, Inc.: A Gross Profit Performance Breakdown

Comparing Gross Profit Trends: Bausch Health vs. BioCryst Pharmaceuticals

__timestampBausch Health Companies Inc.BioCryst Pharmaceuticals, Inc.
Wednesday, January 1, 2014600890000013486000
Thursday, January 1, 2015785380000046361000
Friday, January 1, 2016706300000023654000
Sunday, January 1, 2017617600000023484000
Monday, January 1, 2018602900000020182000
Tuesday, January 1, 2019625100000044734000
Wednesday, January 1, 2020577800000016136000
Friday, January 1, 20216040000000149906000
Saturday, January 1, 20225760000000264233000
Sunday, January 1, 20236198000000326751000
Loading chart...

Unlocking the unknown

A Tale of Two Companies: Gross Profit Trends from 2014 to 2023

In the competitive landscape of pharmaceuticals, Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc. have showcased contrasting trajectories in gross profit over the past decade. Bausch Health, a giant in the industry, consistently reported robust profits, peaking in 2015 with a 30% increase from the previous year. Despite fluctuations, their gross profit remained above $5.7 billion annually, reflecting their market resilience.

Conversely, BioCryst Pharmaceuticals, Inc., a smaller player, demonstrated remarkable growth, especially in recent years. From a modest $13.5 million in 2014, their gross profit surged by over 2300% to $326.8 million in 2023. This growth underscores BioCryst's strategic advancements and increasing market presence.

These trends highlight the dynamic nature of the pharmaceutical sector, where both established giants and emerging innovators play pivotal roles in shaping the industry's future.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025